Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
In brief
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.
Key facts
- Study ID
- NCT04215978
- Run by
- BeiGene
- People needed
- 204
- Starts
- 2020-01-30
- Expected to finish
- 2025-01-24
- Last updated by the study team
- 2025-10-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Valkyrie Clinical Trials — Los Angeles, California, United States
- California Cancer Associates for Research & Excellence (cCARE) — San Diego, California, United States
- UPMC Hillman Cancer Center (Univ Of Pittsburgh) — Pittsburgh, Pennsylvania, United States
- Blacktown Cancer And Haematology Centre — Blacktown, New South Wales, Australia
- Pindara Private Hospital — Benowa, Queensland, Australia
- Princess Alexandra Hospital — Brisbane, Queensland, Australia
- Monash Health — Clayton, Victoria, Australia
- Peter Maccallum Cancer Centre — Melbourne, Victoria, Australia
- Nucleus Network — Melbourne, Victoria, Australia
- Linear Clinical Research — Nedlands, Western Australia, Australia
- Union Hospital Of Tongji Medical College, Huazhong University Of Science And Technology — Wuhan, Hubei, China
- The Second Xiangya Hospital Of Central South University — Changsha, Hunan, China
- Jinan Central Hospital — Jinan, Shandong, China
- Linyi Cancer Hospital — Linyi, Shandong, China
- Affiliated Zhongshan Hospital Of Fudan University — Shanghai, Shanghai Municipality, China
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine — Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China
- University of Malaya Medical Centre — Kuala Lumpur, Malaysia
- Sarawak General Hospital — Kuching, Malaysia
- Auckland City Hospital — Auckland, New Zealand
- National Cancer Center (NCC) — Goyang-si, Gyeonggi-do, South Korea
- Cha Bundang Medical Center, Cha University — Gyeonggido, Gyeonggi-do, South Korea
- The Catholic University of Korea, St. Vincent's Hospital — Suwon, Gyeonggi-do, South Korea
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggido, South Korea
- Severance Hospital Yonsei University Health System — Seoul, Seoul Teugbyeolsi, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.